135 related articles for article (PubMed ID: 340032)
41. Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
Coltman CA; McDaniel TM; Balcerzak SP; Morrison FS; Von Hoff DD
Invest New Drugs; 1983; 1(1):65-70. PubMed ID: 6678857
[TBL] [Abstract][Full Text] [Related]
42. Effect of trimethylcolchicinic acid methyl ether d-tartrate (TMCA) on Hodgkin's and non-Hodgkin's lymphoma.
Stolinsky DC; Jacobs EM; Irwin LE; Pajak TF; Bateman JR
Oncology; 1976; 33(4):151-3. PubMed ID: 798148
[TBL] [Abstract][Full Text] [Related]
43. Results with CCNU in resistant Hodgkin's and non-Hodgkin's lymphoma.
Stolinsky DC; Solomon J; Weiner JM; Bateman JR
Oncology; 1976; 33(5-6):271-3. PubMed ID: 800240
[TBL] [Abstract][Full Text] [Related]
44. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A Phase II trial of the Southwest Oncology Group.
Knight WA; Fabian C; Costanzi JJ; Jones SE; Coltman CA
Invest New Drugs; 1983; 1(3):235-7. PubMed ID: 6678871
[TBL] [Abstract][Full Text] [Related]
45. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.
Miller TP; Dahlberg S; Salmon SE; Williamson SK; Belt RJ; Dana BW; Fisher RI
J Clin Oncol; 1991 Jul; 9(7):1204-9. PubMed ID: 2045860
[TBL] [Abstract][Full Text] [Related]
46. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
47. Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma.
Maurice P; Glidewell O; Jacquillat C; Silver RT; Carey R; Pas AT; Cornell CJ; Burningham RA; Nissen NI; Holland JF
Cancer; 1978 May; 41(5):1658-63. PubMed ID: 348294
[TBL] [Abstract][Full Text] [Related]
48. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group.
Gandara DR; Wold HG; Redmond J; Kohler M; Reynolds R; Wong P; Forsythe J; Fisher K; Lewis B
Semin Oncol; 1986 Mar; 13(1 Suppl 1):14-8. PubMed ID: 3952517
[TBL] [Abstract][Full Text] [Related]
49. A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study.
Miller TP; Cowan JD; Neilan BA; Jones SE
Cancer Chemother Pharmacol; 1986; 16(1):67-9. PubMed ID: 3940222
[TBL] [Abstract][Full Text] [Related]
50. Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone.
Gomez GA; Han T; Ozer H; Henderson ES
Med Pediatr Oncol; 1984; 12(4):239-43. PubMed ID: 6205245
[TBL] [Abstract][Full Text] [Related]
51. Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine).
Ohno R; Yamada K; Hirano M; Shirakawa S; Tanaka M; Oguri T; Kodera Y; Mitomo Y; Ikeda Y; Yokomaku S
J Natl Cancer Inst; 1992 Mar; 84(6):435-8. PubMed ID: 1538420
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials Group.
Bramwell VH; Holdener EE; Siegenthaler P; Ten Bokkel Huinink W; Bruntsch U; Renard J; van Glabbeke M
Eur J Cancer Clin Oncol; 1984 Jun; 20(6):753-9. PubMed ID: 6547674
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Homesley HD; Hacker N; Curry SL
Am J Clin Oncol; 1985 Oct; 8(5):350-2. PubMed ID: 3840643
[TBL] [Abstract][Full Text] [Related]
54. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion.
Jackson DV; Paschold EH; Spurr CL; Muss HB; Richards F; Cooper MR; White DR; Stuart JJ; Hopkins JO; Rich R
Cancer; 1984 Jun; 53(12):2601-6. PubMed ID: 6722721
[TBL] [Abstract][Full Text] [Related]
55. A phase II study of spirogermanium in patients with advanced malignant lymphoma.
Sessa C; ten Bokkel Huinik W; Clavel M; Lev LM; Joss RA; Renard J; Cavalli F
Invest New Drugs; 1989 Jul; 7(2-3):219-22. PubMed ID: 2793376
[TBL] [Abstract][Full Text] [Related]
56. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Chisesi T; Capnist G; de Dominicis E; Dini E
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
[TBL] [Abstract][Full Text] [Related]
57. The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
Hansen HH; Selawry OS; Pajak TF; Spurr CL; Falkson G; Brunner K; Cuttner J; Nissen NI; Holland JF
Cancer; 1981 Jan; 47(1):14-8. PubMed ID: 7006789
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study.
Barlogie B; Crowley J; Salmon SE; Bonnet J; Weick JK; Hayden K
Invest New Drugs; 1994; 12(1):53-5. PubMed ID: 7960607
[TBL] [Abstract][Full Text] [Related]
59. Modulation of chemosensitivity by alpha interferon in multiple myeloma and non-Hodgkin's lymphoma.
Iaffaioli RV; Facchini G; Tortoriello A; Scala S; Pacelli R; La Mura G; Pagliarulo C; Palmieri G; Caponigro F
J Exp Ther Oncol; 1996 Jul; 1(4):226-30. PubMed ID: 9414408
[TBL] [Abstract][Full Text] [Related]
60. PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MULTIPLE MYELOMA AND LYMPHOMA.
DAVIS P
Cancer Chemother Rep; 1964 Aug; 40():51-2. PubMed ID: 14206919
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
